

## Arkansas Statistics

### PCSK9 Inhibitors



### About PCSK9 Inhibitors

PCSK9 inhibitors are designed for patients with extremely high LDL, or “bad,” cholesterol. The drugs are approved by the Food and Drug Administration to treat:

- **Heterozygous familial hypercholesterolemia**, an inherited condition that causes high levels of LDL cholesterol
- **Clinical atherosclerotic cardiovascular disease**, such as heart attacks or strokes.

### Analysis of Health Plan Coverage & Access

A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in Arkansas from January 2017 through December 2017.

#### Key Arkansas Findings



Rejection Rate:  
**36%**



Appeals Rate:  
**18%**



Final Rejections:  
**1,000**

Of health plans that received at least 50 claims for PCSK9 inhibitors, the following had **the highest rates of rejections:**

- Arkansas State Employees **95%**
- BCBS AR **60%**
- Express Scripts **60%**
- Tricare Military Health SVC SYS **47%**

The following had **the lowest rates of rejection:**

- Humana Health Plan **13%**
- Aetna **10%**



The following table details claims data for the Arkansas managed care organizations that received at least 50 claims for PCSK9 inhibitors.

Managed Care Organization	Rejection %	Total Claims	Rejections
ARKANSAS STATE EMPLOYEES	95%	62	59
BCBS AR	60%	379	226
EXPRESS SCRIPTS	60%	52	31
TRICARE MILITARY HEALTH SVC SYS	47%	77	36
CIGNA HEALTHCARE	46%	74	34
UNITED HEALTH GROUP	38%	336	129
CVS HEALTH	33%	403	132
WELLCARE MANAGEMENT GROUP	20%	167	33
HUMANA HEALTH PLAN	13%	454	58
AETNA	10%	276	28

*Data source: National data supplier; Medicare, Medicaid, Medicaid managed care, and commercial plans; January-December 2017.*



The Institute for Patient Access is a physician led nonprofit 501(c)(3) research organization promoting the benefits of the physician-patient relationship in the provision of quality healthcare.

